Danimer Scientific — Q3 2023 Earnings Presentation
12 slides from Danimer Scientific's earnings presentation, Nov 14, 2023
Slide 1: Third Quarter 2023 Earnings Presentation
Third Quarter 2023 Earnings Presentation November 14, 2023
Slide 2: Disclaimer and Forward-Looking Statements
This presentation (“Presentation”) is for informational purposes only. This Presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale w
Slide 3: Fast Facts
FAST FACTS Founded in 2004 (went public in 2020) 480 patents & pending patent applications 15 partnerships with major brands and distributors 263 Teammates 2018 and 2020 recipient of PLASTICS Innovation in Bioplastics Award Locations in Georgia, Kentucky and New York Manufacturer and developer of PH
Slide 4: Proprietary PHA-Based Resins with Disruptive Performance
Certified biodegradable for home compost, natural soil and marine environments Highly-engineered to run on standard manufacturing equipment Indistinguishable from petroleum-based plastic to consumers at end-use Proprietary PHA-Based Resins with Disruptive Performance 1 Switch to PHA-based resin requ
Slide 5: Recent Customer & Business Development Highlights
New program expected to require ~20 million pounds of annual volume of Nodax® cutlery resins; first shipments anticipated mid-year 2024. Bacardi partnership for compostable bottle continues and was extended into other categories to eliminate additional sources of plastic waste. Delta Cafes now launc
Slide 6: Kentucky Manufacturing – Process & Capability
Kentucky Manufacturing – Process & Capability ¹ Intended to illustrate maximum potential at full utilization of design capacity; assumes pricing of $3 per lb. Facility Targets: ~32.5 M LBS of Neat PHA ~65 M LBS Formulated PHA-Based Resin ~$190 M Revenue¹ 6 Continuous innovation effort reveals potent
Slide 7: Q3 2023 Financial Summary
Q3 2023 Financial Summary 3Q23 sales increase versus last year driven entirely by strength in sales of PHA-based resins (up $3.1 million or 58% versus prior year) partially offset by a $1.8 million reduction in sales of PLA-based resins as well as lower R&D and other service revenue. Increased Adjus
Slide 8: Guidance Summary
Revised Adj. EBITDA guidance range of $(40) to $(37) million. Guidance revision reflects later than anticipated timing of revenues associated with customer product launches. Remain confident that volume associated with new programs is intact. Numerous and diversified engagement opportunities for lon
Slide 9: tess, ~ e
AN y . tess, ~ e Zé danimer \ oe soienutic. ‘y __ ABiotechnology Company
Slide 10: EBITDA Reconciliation
danimer scientific EBITDA Reconciliation A Biotechnology Company $ Thousands Net loss ($40,159) ($94,876) Stock-based compensation 14,324 14,305 Interest, net 8,584 553 Depreciation and amortization 7,253 4,585 Income taxes 468 (236) Remeasurement of private warrants (132) (1,607) Strategic reorgani
Slide 11: Adjusted Gross Profit Reconciliation
Adjusted Gross Profit Reconciliation 11
Slide 12: Thank You
a danimer ~ scientific THANK YOU